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Abstrac: Recent studies support cell based therapies for several diseases. Human fetal stem cells have received much at-
tention for developing new therapeutic strategies. Recently, our group and others have successfully isolated and expanded 
karyotypically normal stem cells from an alternative fetal source, the human second trimester amniotic fluid (AF) and per-
formed a systematic phenotypic and molecular analysis. The main characteristics of amniotic fluid stem cells (hAFSCs) 
are their fetal origin, the high number of isolated cells, their wide differentiation properties and their rapid expansion in 
vitro. These characteristics render hAFSCs as a very attractive tool for clinical applications based on cell therapy. The use 
of hAFSC transplantation has been studied in a variety of disease animal models related to bone regeneration, myocardial 
infarction, acute kidney injury, acute hepatic failure, skin injury, ischemic hind limb or cancer. The major aim of this re-
view is to summarize the advent of hAFSCs capabilities into novel therapeutic modalities and discuss their potential use 
in future pre-clinical and clinical studies. 
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INTRODUCTION 
 Regenerative medicine introduces methods to replace or 
regenerate cells, tissue or organs in order to restore and es-
tablish normal function [1]. The three strategies used in re-
generative medicine include cell based therapy, biomaterials 
and scaffolds seeded with cells. In all cases, autologous or 
allogeneic mature functional cells (cell replacement), modi-
fied human cells (cell based gene therapy) or stem cells have 
been used in transplantation [2].  
 There are several parameters to take under consideration 
for a successful cell based therapy. Basic tools for cell trans-
plantation are the scaffolds, usually made by natural or syn-
thetic materials with diverse bioactivity and mechanical 
strength. Scaffolds provide the appropriate environment for 
cellular growth and organogenesis. Recent studies have been 
focused on various applications based on stem cell transplan-
tation seeded into scaffolds [3]. The type of stem cells to-
gether with the selection of the appropriate biomaterial re-
main a critical issue in cell based therapy. Embryonic stem 
cells (ESCs) have great potential due to their unique charac-
teristics, however their use is limited by ethical considera-
tions [4]. In addition, mesenchymal stem cells derived from 
the bone marrow (BM-MSCs) have been used with remark-
able results in animal studies and clinical trials but also re-
vealed several limitations. More recently, research has been 
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focused on stem cells derived from fetal sources. Suchan 
appealing source used in transplantation studies is the amni-
otic fluid (AF) representing a novel and very promising al-
ternative.  
 The cell therapy field has progressed to the forth therapy 
method of global healthcare, among therapies based on 
pharmaceuticals, biological manipulations and medical de-
vises, covering billion dollars per year during the last decade 
[5]. A successful stem cell therapy approach requires a thor-
ough study of the stem cell biology, the availability of well 
established animal models and the development of gene 
transfer methodologies to stem cells Fig. (1). 
 
Fig. (1). Main aspects of stem cell therapy approach. 
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Amniotic Fluid Stem Cells 
 The presence of stem cells in human amniotic fluid was 
firstly described in 2002 by Prusa et al. [6]. hAFSCs can be 
easily obtained from a small volume of second trimester AF, 
collected during routine amniocenteses [6-12] for prenatal 
diagnosis, a procedure with spontaneous abortion rate rang-
ing from 0.06 to 0.5% [7, 13, 14]. hAFSCs represent a het-
erogenous population characterized by a multipotent pheno-
type, high proliferation potential as well as wide differentia-
tion properties [7-12, 15, 16].  
 It was reported that hAFSC culture contains a small 
population of cells expressing the surface antigen c-Kit 
(CD117), the type III tyrosine kinase receptor of the stem 
cell factor [11]. Immunoselection of c-Kit positive hAFSCs 
can be performed by magnetic beads, and the isolated cells 
can be clonally expanded in culture [11]. 
 Another type of hAFSCs is the amniotic fluid mesen-
chymal stem cells (hAF- MSCs) that can be easily obtained 
in culture with estimated frequency in the AF sample be-
tween 0.9% to 1.5% [7]. Recently distinct populations of 
hAF-MSCs were identified, with different proliferation and 
differentiation potential, termed according to their morphol-
ogy, as spindle shaped (SS) and round shaped (RS) [12]. 
Mechanical isolation of both AF-MSC types was conducted, 
and revealed the RS cells as the most abundant population in 
the tested samples. However, 6% of the samples were en-
riched in the SS cell population which can expanded up to 
30-50 passages with a normal karyotype and without show-
ing any tumogenic potential after expansion in culture [7, 
12]. 
Amniotic Fluid Stem Cell as Therapeutic Tool 
 During the last decade there is a strong ethical debate 
primarily concerning the destruction of human embryos for 
the isolation of hESCs. However, other stem cell types such 
as adult stem cells, fetal stem cells and induced pluripotent 
stem cells (iPS) overcome the ESC controversy. Such an 
example, of fetal stem cell population is the hAFSCs. About 
90% of hAFSCs express the transcription factor Oct4, 
known to be expressed in pluripotent human stem cells, sug-
gesting that hAFSCs belong to an intermediate developmen-
tal stage between embryonic and adult stem cells [11, 17]. 
AF is collected during scheduled amniocenteses through 
routine prenatal diagnosis without any ethical concerns [6-9]. 
In comparison, the isolation of hMSCs derived from an adult 
source such as bone marrow is a highly invasive and painful 
procedure and additionally, the number, the proliferation and 
the differentiation capacity of these cells decline with in-
creasing age [18, 19].  
Immunological Properties  
 In cell based therapies, an important limitation is the pos-
sibility of cell rejection. For this reason, hAFSCs represent 
an advantageous cell type for allogeneic transplantation as 
they have an inherently low immunogenic profile exhibiting 
low expression of HLA-ABC and no HLA-DR antigens [7, 
8, 11, 12]. Therefore, the use of hAFSCs reduces the risk of 
cell rejection and the potential of graft versus-host disease. 
Role in Anti-inflammatory Response 
 Much of excitement surrounds the ability of hAFSCs to 
suppress inflammatory responses. c-Kit positive hAFSCs 
have been shown to inhibit the activation of lymphocytes in 
a dose dependent manner involving both direct and indirect 
interaction between stem cells and their secreted factors with 
the immune cells [20]. hAFSCs released several cytokines 
mediating in inflammatory response such as growth related 
oncogene (GRO), monocyte chemotactic protein family 
(MCP) as well as interleukin-6 (IL-6) [20]. Additionally, in 
our studies, we analyzed the cytokines secreted in the condi-
tioned medium derived from human SS-AF-MSCs [21]. It 
was observed that SS-AF-MSCs expressed a number of cy-
tokines and growth factors such as transforming growth fac-
tor beta-1 (TGF-1) and granulocyte macrophage colony 
stimulating factor (GM-CSF), responsible for downregulat-
ing the systemic inflammation. Therefore, hAFSCs exhibit 
immunomodulatory potential resembling MSCs. 
Virus Mediated Gene Transfer 
 The scenario of using hAFSCs for therapeutic applica-
tions requires these cells to be genetically modified in order 
to deliver systematically the desired therapeutic gene to the 
injured area. To this end, Grifani et al. showed that hAFSCs 
can be transduced with adenovirus vectors with high effi-
ciency [22]. In addition, no alterations on cell phenotype and 
their differentiation properties were observed. In our studies, 
human SS-AF-MSCs were successfully transduced in a virus 
dose-depended manner with GFP third generation lentivirus 
[12]. No silencing effects were noticed over the multiple 
culture passaging, maintaining the GFP expression. Also, 
GFP transduced SS-AF-MSCs retained their in vitro differ-
entiation potential. These findings provide a proof of princi-
ple for designing modified hAFSCs for therapeutic applica-
tions. 
Absence of Teratoma Formation in vivo  
 A major concern in stem cell based therapy is the forma-
tion of teratomas in vivo. However, no tumor formation was 
observed even 3 months after transplantation of human SS-
AF-MSCs or c-Kit positive hAFSCs into immune-deficient 
mice [11, 12]. In contrast, hESCs often form teratocarcino-
mas when transplanted in vivo, acquiring frequently chromo-
somal aberrations [23-25].  
Preclinical Studies 
Animal Models 
 Animal models are recognized as powerful tools in re-
search associated with several diseases. Clinical testing and 
development of novel therapeutic schemes depend on the 
availability of well established animal models. The use of 
preclinical models provides new sights in tissue engineering 
and enables cell transplantation for further investigation on 
the repair and the replacement of damaged tissues or organs. 
Well established transplantation models are needed to test 
the ability of transplanted cells to ameliorate the disease 
symptoms and also examine potential side effects [26]. In 
several studies, AFSCs have been used for autologous trans-
plantation in respective animal models. This review provides 
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an overview on the use of human AFSCs in animal models 
resembling severe diseases.  
Bone Defects 
 Bone defects are commonly caused by injury, congenital 
disorders or surgery for bone cancer. Treatment of extensive 
bone defects indicates autologous bone replacement or the 
use of bone enhancement materials. An alternative approach 
has been focused on engineering biological bone grafts by 
culturing cells within 3D scaffolds under appropriate condi-
tions for bone formation. 
 For the first time, De Coppi and his group presented the 
formation of tissue engineered bone from printed constructs 
of osteogenically differentiated hAFSCs in immune-deficient 
mice [11]. c-Kit positive hAFSCs were placed into an algi-
nate/collagen composite gel, creating scaffold/cell constructs 
that were incubated for one week under osteogenic condi-
tions prior implantation. The implanted printed constructs 
exhibited high mineralized tissue after 8 weeks as examined 
by histological analyses. The production of hard tissue 
within the cell seeded scaffolds was observed 4-5 months 
post implantation, confirming in this way the formation of 
high density tissue engineered bone [11].  
Myocardial Infarction  
 Myocardial infarction is characterized by reduced blood 
supply of the heart muscle, usually due to atherosclerosis of 
the coronary arteries. Recently, stem cell therapy has been 
considered effective for treating ischemic heart disease. In-
terestingly, it has been shown that hAF-MSCs express car-
diac specific genes under appropriate culture conditions and 
are able to integrate into normal and ishaemic heart explants, 
where they can differentiate into cardiocyte-like cells [27].  
 Chiavegato et al. investigated for the first time the in vivo 
therapeutic effect of hAFSCs in a rat model of myocardial 
infarction [28]. Left anterior descending coronary artery in 
female Sprague-Dawley rats was identified and ligated with 
a 7-0 polypropylene suture. After 20 min, immunomagnetic 
sorted hAFSCs were transplanted in ischemic heart of im-
mune-competent or immuno-deficient animals in the periph-
ery of the damaged area in three distinct sites. Despite all 
expectations, transplanted hAFSCs were acutely rejected, 
because of the recipient’s immune response whereas, in 
some cases, hAFSCs gave rise to chondro-osteogenic masses 
in the heart [28].  
 In a recent publication, Delo et al. confirmed the forma-
tion of such masses in the ventricular wall of infracted rats 
[29]. These data suggested that the chondro-osteogenic 
masses were formed independently of the hAFSCs injection 
into the myocardium. In particular, masses were correlated 
with the infarction size and the fractional shortening [29]. 
Sciatic Nerve Injury 
 The first evidence that hAFSCs have been able to survive 
and migrate after transplantation into the striatum of normal 
and ischemic rats was presented in 2007 by Cipriani et al. 
[30]. Notably, grafted cells migrated in several brain regions 
in normal animals and also intended to move to the injured 
regions. Based on these important findings many efforts 
have been focused on hAFSCs as a promising treatment on 
nerve injuries. 
 The peripheral nerve regeneration using hAF-MSCs was 
studied for the first time by Pan et al. [31]. A sciatic nerve 
injury was generated using Sprague Dawley rats. The left 
sciatic nerve was exposed under microscope examination 
and pressure was applied using a vessel clamp. The sciatic 
nerve crush effected nerve function, disrupted nerve integrity 
and provoked inflammatory response [31]. hAF-MSCs were 
embedded in fibrin glue containing the woven surgical and 
transplanted into the injured site immediately after crush. 
The rejection of cell transplantation was prevented with the 
use of cyclosporine. Granulocyte-colony stimulating factor 
(G-CSF) was also intraperitoneal administrated. This com-
bined treatment showed increased nerve myelination and a 
significant improvement in motor function. G-CSF that was 
also expressed in hAF-MSCs, prevented the anti-apoptotic 
effect on implanted hAF-MSCs and in the same time had 
anti-imflammatory role [31].  
 In another study, the same group reported the beneficial 
effect of hyperbaric oxygen (HBO) on transplanted hAF-
MSCs in peripheral nerve regeneration [32]. The sciatic 
nerve injury model was generated as mentioned before and 
the transplantation of hAF-MSCs was performed using the 
same protocols. The rats received HBO after transplantation 
for seven days. HBO has been shown to inhibit pro-
inflammatory cytokines synthesis leading to an anti-
inflammatory effect. The peripheral nerve regeneration ob-
served may be related to the suppression of apoptosis in im-
planted hAF-MSCs and in the reduction of the inflammatory 
response [32]. 
 Using as a backbone the same sciatic nerve injury model 
and the implantation method of hAFSCs, Pan et al. also in-
vestigated the combined therapeutic effect of fermented soy-
bean extracts, termed as Natto [33]. Administration of Natto 
is proposed to rescue hAFSCs and Schwann cells from apop-
tosis resulting to neurological improvement. 
 The sciatic nerve crush model was also studied by Cheng 
et al. [34]. In particular, hAF-MSCs were modified to ex-
press human glia cell line-derived meurotrophic factor 
(GDNF) using adenoviral vector. GDNF-AF-MSCs were 
labeled with lipophilic fluorescence marker and then embed-
ded in matrigel and transplanted to the injured nerve. To 
avoid rejection, cyclosporine was also used in this study. 
Rats treated with GDNF-AF-MSCs showed improvement in 
motor function and early regeneration of neurofilaments, as 
well as increased proliferation rate of Schwann cells in the 
distal end of the nerve. Simultaneously, nerve regeneration 
in the later phase was observed through increased myelina-
tion, vascular organization and decreased number of vascu-
oles [34].  
 A later publication came in 2012, regarding the sciatic 
nerve injury model by Yang et al. [35]. hAF-MSCs were 
intravenously administered according to their stromal cell-
derived factor-1 (SDF-1) expression immediately or 7 
days after injury. SDF-1 was overexpressed in nerve and 
muscle after injury together with the chemokine receptor 
type-4 (CXCR-4). More importantly, SDF-1 increased the 
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migration and the wound healing properties of hAF-MSCs, 
supporting their engraftment in muscle and nerve. Trans-
planted cells were found in significant amounts in spleen, 
muscle and nerve, when administrated 7 days after the in-
jury. In this study, neurobehavior improvement was ob-
served based on the sciatic function index, the electrophysi-
ology test and the computerized gait analysis. hAF-MSCs 
treatment showed regeneration of nerve and muscle tissue 
function by an increase in the number of axons, together 
with nerve myelination and high expression of neurotrophic 
factors and acetylcholine receptor. These findings suggested 
a nerve regeneration scenario focused on hAF-MSCs for 
peripheral nerve disorder [35]. 
Acute Kidney Injury  
 Acute tubular cell injury and renal dysfunction causes 
acute tubular necrosis. In 2007, Perin et al. reported renal 
differentiation of c-Kit positive AFS cells [36] and three 
years later showed the therapeutic potential of these cells in a 
mouse model for acute tubular necrosis [37]. The mouse 
model was generated by intramuscular injection with 50% 
hypertonic glycerol solution in water, following 22 hours 
deprivation of water. hAFSCs were labeled with CM-Dil and 
then carefully injected into the renal cortex of both kidneys. 
Evidence showed that c-Kit positive hAFSCs were present in 
the kidney for 21 days after transplantation and were differ-
entiated into cells expressing adult proximal and distal tubu-
lar agglutinins. The levels of serum creatinine and blood urea 
nitrogen together with a decreased number of damaged tu-
bules suggested that hAFSCs improved acute tubular injury. 
In addition, hAFSCs were observed to modulate the immune 
response expressing anti-inflammatory cytokines [37].  
 Another study by Hauser et al. also demonstrated that 
hAFSCs induce the recovery of murine experimental acute 
kidney injury [38]. The SCID acute kidney injury mice 
model was generated by intramuscular injection of glycerol, 
exposing the kidney to myoglobin and iron, creating in this 
way tubular injury. Transplanted hAFSCs were detected 
within the peritubular capillaries localized into the inter-
stitium, but they did not integrate into the renal tissue. The 
intravenous injection of hAFSCs improved the renal func-
tion, enhanced tubular cell proliferation and reduced apopto-
sis. Also, the produced cytokines and growth factors in the 
conditioned medium of hAFSCs, suggested a combined 
mechanism for their therapeutic properties in acute kidney 
injury. More specifically, LIF (Leukemia inhibitory factor), 
an important factor in renal development, has been expressed 
by hAFSCs, inducing the proliferation rate of tubular epithe-
lial cells [38]. 
 Recently, the therapeutic effect of hAFSCs in acute kid-
ney injury was also studied by Rota et al. [39]. The acute 
kidney injury murine model was generated by administrated 
the nephrotoxic drug, cisplatin, to NOD-SCID mice. c-Kit 
positive hAFSCs were intravenously injected 24 hours after 
injury. Limited tubular damage, improvement of the renal 
function and plolonged survival were observed. Transplanta-
tion of c-Kit positive hAFSCs was shown to inhibit apopto-
sis of tubular cells through the induction of the serine-
threonine kinase Akt and in the same time to promote the 
proliferation of the renal tubular cells. These therapeutic 
effects were due to the paracrine action of the transplanted c-
Kit positive hAFSCs that secreted factors such as IL-6, 
VEGF and SDF-1. In addition, this study suggested that 
hAFSCs pretreated with glial cell line derived neurotrophic 
factor (GDNF) enhanced their therapeutic effect by increas-
ing the production of growth factors and the expression of 
receptors involved in cell homing and survival [39]. 
Acute Hepatic Failure  
 The description of acute hepatic failure involves the rapid 
loss of liver function, resulting in coagulopathy and hepatic 
encephalopathy. Recent research has been focused on the use 
of stem cell regenerative strategies, indicating an attractive 
alternative approach for liver repair. 
 In our recent studies, the effect of the transplantation of 
human SS-AF-MSCs or their conditioned medium was ex-
amined in acute hepatic failure [21]. NOD-SCID mice have 
been injected intraperitoneally with carbon tetrachloride 
(CCL4) to generate the acute hepatic failure model. Twenty-
four hours after the administration of CCL4, hAF-MSCs 
were transplanted in treated mice by intrahepatic or intraperi-
toneal injection. Interestingly, hAF-MSCs were engrafted 
into CCL4 injured livers, successfully downregulated the 
systemic inflammation and improved the liver function. We 
also observed a significant improvement in the liver function 
after intrahepatic delivery of conditioned medium from hAF-
MSCs, due to the cytokines and the growth factors that were 
secreted. Cytokines such as IL-10, IL-27, IL-17E, IL-12p70, 
IL-1 and IL-1ra, responsible for inducing local and sys-
temic downregulation of pro-inflammatory mediators, were 
detected. This study clearly indicated the therapeutic effect 
of hAF-MSCs and point out the role of the paracrine effect 
and the secreted molecules from donor cells [21]. 
Skin Wounds 
 Injuries can become chronic wounds creating a signifi-
cant burden for patients. Effective treatment of skin injuries 
requires full understanding of normal healing process. Re-
cent studies provided evidence that fetal stem cells represent 
a promising tool for wound repair and tissue regeneration.  
 Yoon et al. generated a skin injury mouse model, creat-
ing two 2-mm full thickness excisional skin wounds on the 
side of the midline in each animal, in order to study the 
paracrine factors released by hAF-MSCs and their role in the 
wound healing process [40]. The conditioned medium of 
hAF-MSCs (hAF-MSC-CM) was subcutaneously injected 
around the wound and also topically applied in a donut 
shaped silicone splint on the wound. Using an antibody 
based protein array and ELISA method it was revealed that 
hAF-MSC-CM is comprised of cytokines and chemokines 
such as TNF-, VEGF, TGF-, Leptin, IL6 and IL8 that play 
an important role in normal wound healing. In particular, 
hAF-MSC-CM through these secreted molecules induced the 
proliferation rate of dermal fibroblasts enhancing the wound 
healing process via TGF-/SMAD2 pathway. These data 
suggested that hAF-MSC-CM may represent a useful tool for 
tissue repair [40].  
 Recently, Mirabella et al. generated a fasciocutaneous 
flap model using Sprague Dawley rats [41]. Specifically, 
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abdominal skin of rats was depilated and a square fasciocu-
taneous flap was elevated in a cranial to caudal direction as 
to be detached from the abdominal muscle layer. hAF-MSC-
CM was embedded to a gelatin membrane and then delivered 
on the muscular layer. Seven days after, the ischemic area 
was re-vascularized by the recruitment of endothelial pro-
genitor cells as a result of the pro-angiogenic soluble factors 
secreted by hAF-MSCs. In particular, angiogenic growth 
factors and cytokines were secreted topically into the skin 
flap of the ischemic rat model, promoting the endogenous 
repair by recruiting endothelial progenitor cells [41].  
Ischemic Hind Limb 
 Recently, it has been documented that hAFSC secretome 
was responsible for enhancing vasculogenesis and was capa-
ble of evoking a strong angiogenic response in an ischemic 
mouse model [42]. Ischemia was generated by unilateral 
ligation of the right femoral artery immediately distal to the 
origin of the deep femoral branch. c-Kit positive hAFSCs 
were embedded in two different biomaterials (polyurethane 
and matrigel) and implanted into the back of the mice. 
Twenty days after the transplantation, big blood vessels and 
collaterals were observed. In addition, the injured skin was 
repaired and vessel-perfused appeared. The conditioned me-
dium was also added to liquid matrigel and then injected to 
the ischemic models. Improvement in the ischemia was ob-
served through the promotion of neo-arteriogenesis. Accord-
ing to this study, hAFSC secretome was responsible for the 
stimulation of neo-arteriogenesis. Moreover, analysis of the 
conditioned medium derived from hAFSCs revealed the 
presence of known pro-angiogenic and anti-angiogenic fac-
tors, such as vascular endothelial growth factor (VEGF), 
stromal cell-derived factor-1 (SDF-1), interleukin 8 (IL-8), 
monocyte chemotactic protein-1 (MCP-1) and two angio-
genesis inhibitors, interferon-gamma (IFN) and interferon 
gamma-induced protein 10 (IP-10) [42]. 
Cancer 
 Recent studies have proposed hAFSCs as cellular vehi-
cles to deliver anti-cancer agents selectively to the tumor 
sites because of their homing properties in tumors [43]. 
 An attempt to apply the stem cell based treatment in 
glioblastoma, the most malignant brain tumor, has been de-
scribed recently from Yin et al. [44]. hAF-MSCs were stably 
transduced to deliver endostatin, an inhibitor of angiogene-
sis, and secreted carboxylesterase 2 (sCE2) that converts the 
prodrug CPT11 to the more active metabolite, SN-38. 
BALB/c nude mice were transplanted with U87MG cells 
forming brain tumor and then hAF-MSC-endostatin-sCE2 
were stereotactically injected into the left striata. Mice were 
also received CPT11 intravenously. Findings of this study 
suggested that hAF-MSC-endostatin-sCE2 cells remarkably 
decreased the vessel density, suppressed the cell proliferation 
rate and increased cell death in presence of CPT11. In paral-
lel, a reduction of the nestin positive glioma stem cells and 
an increase in GFAP
+
 and S100+ differentiated cells were 
reported [44]. 
 Bitsika et al. introduced for the first time hAF-MSCs as 
useful tool for the treatment of a bladder tumor model [45]. 
Bladder cancer is a severe malignancy arising from the 
epithelial lining of the urinary bladder. In this study, im-
mune-deficient mice were injected subcutaneously with 
T24M cells, an invasive and metastatic bladder cancer cell 
line and 10 days later tumors were established. hAF-MSCs 
were transduced with lentivirus carrying the sequence of 
human IFN, resulting to the secretion of the IFN cytokine 
from the hAF-MSCs. These cells were administered in 3 
weekly doses into the lateral tail vein of each animal and 
have been successfully migrated at the tumor site. Inhibition 
of the malignant tumor growth was detected, together with 
prolonged survival of mice in presence of IFN-AF-MSCs. 
The mechanism proposed is based not only on the secretion 
of IFN but also on the paracrine effect generated by the 
produced cytokine [45].  
 A later study by Kang et al., investigated the therapeutic 
potential of hAFSCs in breast cancer [46]. Breast cancer is 
the most common invasive cancer in women and the treat-
ment is based on surgery, chemotherapy and radiation with 
many side effects. A novel chemotherapy approach using 
genetically engineered hAFSCs to deliver suicide genes, 
such as cytosine deaminase (CD) and herpes simplex virus 
thymidine kinase (HSV-TK) was reported [46]. Suicide 
genes cause tumor cells death through apoptosis or pro-
grammed cell death, converting non-toxic prodrugs into 
toxic metabolites. In particular, CD gene converts prodrug 5-
fluorocytosine (5-FC) into a more toxic nucleotide analog, 5-
fluorouracil (5-FU), enhancing cell death through the forma-
tion of DNA double strand breaks [47]. Also, HSV-TK gene 
induces apoptosis, converting phosphorylate ganciclovir 
(GCV) into toxic metabolites [48]. hAFSCs were engineered 
to express these two suicide genes (AF.CD-TK) through a 
retroviral vector with CD-TK fusion gene. Female BALB/c 
nude mice were injected subcutaneously with matrigel ma-
trix contacting MDA-MB-231 cells into the right mammary 
fat pads. Mice developed tumors after 7 weeks and then were 
treated with the AF.CD-TK expressing cells in presence of 
5-FU and GCV prodrugs. It was reported that this treatment 
did not alter the structure of the breast tissue compare to the 
drug treatment. More importantly, AF.CD-TK expressing 
cells were detected at the tumor site and found to promote 
significantly the reduction of the tumor volume and weight 
without causing any undesirable side effects. Also, the pres-
ence of receptors such as c-Kit and CXCR4 in AF.CD-TK 
expressing cells, may facilitate their tropism to the tumor 
[46].  
Bladder Dysfunction in Parkinson Disease 
 Parkinson disease is a degenerative disorder of the cen-
tral nervous system. The progressive loss of dopamine gen-
erating cells in the substantia nigra leads to motor defects 
early in the course of the disease. Later, lower urinary symp-
toms may also be developed, resulting in a marked reduction 
in the quality of life Parkinson’s patients. Dopamine agonists 
have been used in order to treat the early motor symptoms 
but these drugs eventually become ineffective. In these se-
vere cases surgery and deep brain stimulation have been 
used, whereas currently active research directions are fo-
cused on gene therapy and stem cell transplants [49]. 
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 Recent studies described the effect of cell therapy based 
on hAFSCs in bladder dysfunction using a well established 
rat model of Parkinson disease [50]. Soler et al. developed a 
dopaminergic lesion animal model in order to study the late 
phase of Parkinson disease, injecting the neurotoxin 6-
OHDA into the nigrostriatal pathway. Despite motor dys-
function, rats emerged bladder hyperactivity after the lesion. 
Transplantation of c-Kit positive hAFSCs significantly im-
proved several urodynamic parameters but after 28 days the 
improvement recessed since cells were not detected, proba-
bly due to host immune reaction. More importantly, mice 
transplanted with hAFSCs revealed lower number of dead 
dopaminergic cells in the substantia nigra. It was proposed 
that hAFSCs after transplantation created a neuroprotective 
environment increasing the expression of various cytokines, 
such as IL-6, IL-1 and IL-1. In addition, hAFSCs express-
ing the enzyme superoxide dismutase-2 (SOD-2) in vivo, 
contributed to the improvement of the oxidative stress cre-
ated by the injection of 6-OHDA [50]. 
CONCLUSIONS 
 Cell based therapy is a promising strategy for treating 
numerous severe diseases. During the last years researchers 
have been focused on identifying the most appropriate stem 
cell type that can be used in such treatments providing reme-
dial results. Extensive studies in several animal models sug-
gested that hAFSCs may represent a valid alternative for 
regenerative medicine in the future. hAFSCs are thought to 
fit into an intermediate stage on the developmental contin-
uum between embryonic and adult stem cells, mainly be-
cause of their fetal origin, their self-renewal capacity and 
their plasticity. Additionally, hAFSCs are easily accessible 
and exhibit minor or no ethical controversies. Another im-
portant characteristic is related to their immunological prop-
erties, reducing the risk of cell rejection and the potential of 
graft versus–host disease. More importantly, no evidence of 
tumorigenicity after hAFSC transplantation has yet been 
reported. The therapeutic effect observed by hAFSC trans-
plantation clearly indicated that these cells are a effulgent 
source of well characterized immunomodulatory cells that 
exhibit extensive possibility for banking in the future and 
can be used for both autologous and allogeneic cell based 
therapy with promising remarkable results.  
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Table 1. Summary of hAFSC treatment into several disease animal models 
Disease Model Cell type Transplantation method References Date 
Bone Defects c-Kit+ hAFSCs Aliginate/collagen gel De Coppi et al. [11] 2007 
Myocardial Infraction c-Kit + hAFSCs Injection at the injured site Chiavegato et al. [28] 2007 
 c-Kit + hAFSCs Injection at the injured site Delo et al. [29] 2011 
Sciatic Nerve Injury hAF-MSCs Fibrin glue gel Pan et al. [31-33] 2009 
 hAF-MSCs Matrigel Cheng et al. [34] 2010 
 hAF-MSCs i.v injection Yang et al. [35] 2012 
Acute Kidney Injury c-Kit + hAFSCs Injection at the injured site Perin et al. [37] 2010 
 hAFSCs  i.v injection Hauser et al. [38] 2010 
 c-Kit + hAFSCs i.v injection Rota et al. [39] 2012 
Acute hepatic Failure hAF-MSCs/hAF-MSC-CM i.p / intrahepatic injection Zagoura et al. [21] 2012 
Skin Injury hAF-MSC-CM Silicone splint Yoon et al. [40] 2010 
 hAF-MSC-CM Gelatin membrane Mirabella et al. [41] 2012 
Ischemic Hind Limb c-Kit + hAFSCs/ c-Kit + hAFSCs-CM Polyurethane/Matrigel/Liquid  
matrigel 
Mirabella et al. [42] 2011 
Cancer hAF-MSCs Injection at the injured site Yin et al. [44] 2011 
 hAF-MSCs i.v injection Bitsika et al. [45] 2011 
 hAFSCs Injection at the tumor site Kang et al. [46] 2012 
Bladder Dysfunction in 
Parkinson Disease 
c-Kit + hAFSCs Injection at the injured site Soler et al. [50] 2012 
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